Breath Aldehyde Profiling using PFBHA-GC/MS as a Prostate Cancer Biomarker

Single-compound aldehyde profiling with PFBHA-GC/MS failed to differentiate PCa from controls, primarily due to low analyte detection rates and minimal between-group contrasts. Enhanced-sensitivity platforms (e.g., GC×GC-HRMS or MEMS-based pre-concentrators) and multi-component VOC signatures coupled with rigorous control of smoking and ambient confounders are needed before breath testing can contribute meaningfully to prostate cancer screening.